JP2003530320A - 甲状腺疾患の治療法 - Google Patents
甲状腺疾患の治療法Info
- Publication number
- JP2003530320A JP2003530320A JP2001559492A JP2001559492A JP2003530320A JP 2003530320 A JP2003530320 A JP 2003530320A JP 2001559492 A JP2001559492 A JP 2001559492A JP 2001559492 A JP2001559492 A JP 2001559492A JP 2003530320 A JP2003530320 A JP 2003530320A
- Authority
- JP
- Japan
- Prior art keywords
- thyroid
- botulinum toxin
- neurotoxin
- cells
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000024799 Thyroid disease Diseases 0.000 title claims description 53
- 208000021510 thyroid gland disease Diseases 0.000 title claims description 47
- 238000011282 treatment Methods 0.000 title description 64
- 210000001685 thyroid gland Anatomy 0.000 claims abstract description 182
- 108030001720 Bontoxilysin Proteins 0.000 claims abstract description 125
- 229940053031 botulinum toxin Drugs 0.000 claims abstract description 117
- 239000002581 neurotoxin Substances 0.000 claims abstract description 98
- 231100000618 neurotoxin Toxicity 0.000 claims abstract description 98
- 238000000034 method Methods 0.000 claims abstract description 81
- 101710138657 Neurotoxin Proteins 0.000 claims abstract description 75
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 claims abstract description 47
- 208000003532 hypothyroidism Diseases 0.000 claims abstract description 47
- 239000005495 thyroid hormone Substances 0.000 claims abstract description 47
- 229940036555 thyroid hormone Drugs 0.000 claims abstract description 47
- 230000002989 hypothyroidism Effects 0.000 claims abstract description 46
- 206010020850 Hyperthyroidism Diseases 0.000 claims abstract description 41
- 230000028327 secretion Effects 0.000 claims abstract description 34
- 210000000331 sympathetic ganglia Anatomy 0.000 claims abstract description 18
- 102000055006 Calcitonin Human genes 0.000 claims abstract description 10
- 108060001064 Calcitonin Proteins 0.000 claims abstract description 10
- 229960004015 calcitonin Drugs 0.000 claims abstract description 10
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims abstract description 10
- 230000001603 reducing effect Effects 0.000 claims abstract description 7
- 108010057266 Type A Botulinum Toxins Proteins 0.000 claims description 62
- 210000004027 cell Anatomy 0.000 claims description 61
- 229940094657 botulinum toxin type a Drugs 0.000 claims description 59
- 230000001965 increasing effect Effects 0.000 claims description 19
- 210000003771 C cell Anatomy 0.000 claims description 14
- 241000193403 Clostridium Species 0.000 claims description 9
- 208000037147 Hypercalcaemia Diseases 0.000 claims description 8
- 208000013038 Hypocalcemia Diseases 0.000 claims description 8
- 230000000148 hypercalcaemia Effects 0.000 claims description 8
- 208000030915 hypercalcemia disease Diseases 0.000 claims description 8
- 230000000705 hypocalcaemia Effects 0.000 claims description 8
- 230000002950 deficient Effects 0.000 claims description 6
- 241000894006 Bacteria Species 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 10
- 230000004936 stimulating effect Effects 0.000 abstract description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract description 6
- 239000011575 calcium Substances 0.000 abstract description 6
- 229910052791 calcium Inorganic materials 0.000 abstract description 6
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 108700012359 toxins Proteins 0.000 description 36
- 101710117542 Botulinum neurotoxin type A Proteins 0.000 description 35
- 229940089093 botox Drugs 0.000 description 35
- 231100000765 toxin Toxicity 0.000 description 32
- 239000003053 toxin Substances 0.000 description 31
- 108010074523 rimabotulinumtoxinB Proteins 0.000 description 27
- 210000003205 muscle Anatomy 0.000 description 25
- 210000001519 tissue Anatomy 0.000 description 25
- 239000000203 mixture Substances 0.000 description 24
- 230000001713 cholinergic effect Effects 0.000 description 23
- 238000009472 formulation Methods 0.000 description 23
- 230000000694 effects Effects 0.000 description 20
- 210000002569 neuron Anatomy 0.000 description 20
- 238000002347 injection Methods 0.000 description 19
- 239000007924 injection Substances 0.000 description 19
- 208000024891 symptom Diseases 0.000 description 18
- 230000002889 sympathetic effect Effects 0.000 description 17
- 238000011200 topical administration Methods 0.000 description 17
- 208000023328 Basedow disease Diseases 0.000 description 16
- 208000015023 Graves' disease Diseases 0.000 description 14
- 230000009471 action Effects 0.000 description 14
- 210000005036 nerve Anatomy 0.000 description 14
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 13
- 229960004373 acetylcholine Drugs 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 238000001356 surgical procedure Methods 0.000 description 13
- 208000003098 Ganglion Cysts Diseases 0.000 description 12
- 208000005400 Synovial Cyst Diseases 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 108010069038 botulinum toxin type F Proteins 0.000 description 11
- 238000010255 intramuscular injection Methods 0.000 description 11
- 239000007927 intramuscular injection Substances 0.000 description 11
- 230000009467 reduction Effects 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 210000002990 parathyroid gland Anatomy 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 8
- 210000001367 artery Anatomy 0.000 description 8
- 230000001537 neural effect Effects 0.000 description 8
- 210000002820 sympathetic nervous system Anatomy 0.000 description 8
- 241000193155 Clostridium botulinum Species 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 102000011923 Thyrotropin Human genes 0.000 description 7
- 108010061174 Thyrotropin Proteins 0.000 description 7
- 108010069023 botulinum toxin type E Proteins 0.000 description 7
- 210000002932 cholinergic neuron Anatomy 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 230000030214 innervation Effects 0.000 description 7
- 239000002858 neurotransmitter agent Substances 0.000 description 7
- 230000001734 parasympathetic effect Effects 0.000 description 7
- 229940043671 antithyroid preparations Drugs 0.000 description 6
- XMBWDFGMSWQBCA-RNFDNDRNSA-M iodine-131(1-) Chemical compound [131I-] XMBWDFGMSWQBCA-RNFDNDRNSA-M 0.000 description 6
- 210000003801 laryngeal nerve Anatomy 0.000 description 6
- 210000005037 parasympathetic nerve Anatomy 0.000 description 6
- 230000003248 secreting effect Effects 0.000 description 6
- 230000009885 systemic effect Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 208000005057 thyrotoxicosis Diseases 0.000 description 6
- 210000003462 vein Anatomy 0.000 description 6
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 5
- 206010018498 Goitre Diseases 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 206010033799 Paralysis Diseases 0.000 description 5
- 150000001413 amino acids Chemical group 0.000 description 5
- 239000003200 antithyroid agent Substances 0.000 description 5
- 108700017751 botulinum toxin type C Proteins 0.000 description 5
- 108010069022 botulinum toxin type D Proteins 0.000 description 5
- 108010069071 botulinum toxin type G Proteins 0.000 description 5
- 238000002591 computed tomography Methods 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 210000000744 eyelid Anatomy 0.000 description 5
- 210000003195 fascia Anatomy 0.000 description 5
- 210000004907 gland Anatomy 0.000 description 5
- 210000000867 larynx Anatomy 0.000 description 5
- PMRYVIKBURPHAH-UHFFFAOYSA-N methimazole Chemical compound CN1C=CNC1=S PMRYVIKBURPHAH-UHFFFAOYSA-N 0.000 description 5
- 230000002093 peripheral effect Effects 0.000 description 5
- 230000002797 proteolythic effect Effects 0.000 description 5
- 238000001959 radiotherapy Methods 0.000 description 5
- 210000002955 secretory cell Anatomy 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 210000003437 trachea Anatomy 0.000 description 5
- 108010088751 Albumins Proteins 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 4
- 108010079650 abobotulinumtoxinA Proteins 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000002638 denervation Effects 0.000 description 4
- 229940098753 dysport Drugs 0.000 description 4
- 208000030533 eye disease Diseases 0.000 description 4
- 210000004186 follicle cell Anatomy 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 210000004126 nerve fiber Anatomy 0.000 description 4
- 210000000715 neuromuscular junction Anatomy 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 210000001002 parasympathetic nervous system Anatomy 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 229960002662 propylthiouracil Drugs 0.000 description 4
- 230000000306 recurrent effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 210000002027 skeletal muscle Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 3
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 3
- 208000003164 Diplopia Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 208000019695 Migraine disease Diseases 0.000 description 3
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 3
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 3
- 208000010428 Muscle Weakness Diseases 0.000 description 3
- 206010028372 Muscular weakness Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 108090000445 Parathyroid hormone Proteins 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 241000223503 Platysma Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 210000001789 adipocyte Anatomy 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000003403 autonomic nervous system Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 206010005159 blepharospasm Diseases 0.000 description 3
- 230000000744 blepharospasm Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 210000003451 celiac plexus Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 230000028023 exocytosis Effects 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 210000000609 ganglia Anatomy 0.000 description 3
- 229930195712 glutamate Natural products 0.000 description 3
- 201000003872 goiter Diseases 0.000 description 3
- 208000013403 hyperactivity Diseases 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 230000005923 long-lasting effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 210000002161 motor neuron Anatomy 0.000 description 3
- 229960002715 nicotine Drugs 0.000 description 3
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 3
- 229960002748 norepinephrine Drugs 0.000 description 3
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 229960002178 thiamazole Drugs 0.000 description 3
- 210000000534 thyroid cartilage Anatomy 0.000 description 3
- 229940034208 thyroxine Drugs 0.000 description 3
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 3
- 230000001515 vagal effect Effects 0.000 description 3
- 210000001186 vagus nerve Anatomy 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 108060003345 Adrenergic Receptor Proteins 0.000 description 2
- 102000017910 Adrenergic receptor Human genes 0.000 description 2
- 229930003347 Atropine Natural products 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 208000003508 Botulism Diseases 0.000 description 2
- 241000193171 Clostridium butyricum Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000003807 Graves Disease Diseases 0.000 description 2
- 208000001204 Hashimoto Disease Diseases 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 2
- 208000000038 Hypoparathyroidism Diseases 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 102100036893 Parathyroid hormone Human genes 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 108010005730 R-SNARE Proteins Proteins 0.000 description 2
- 208000032023 Signs and Symptoms Diseases 0.000 description 2
- 208000004350 Strabismus Diseases 0.000 description 2
- 102000002215 Synaptobrevin Human genes 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000001800 adrenalinergic effect Effects 0.000 description 2
- 230000003208 anti-thyroid effect Effects 0.000 description 2
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 2
- 229960000396 atropine Drugs 0.000 description 2
- 239000002876 beta blocker Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 231100001103 botulinum neurotoxin Toxicity 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- 210000005056 cell body Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 210000003109 clavicle Anatomy 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000000762 glandular Effects 0.000 description 2
- 230000004190 glucose uptake Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 210000000548 hind-foot Anatomy 0.000 description 2
- 229960004716 idoxuridine Drugs 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004630 mental health Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000002536 noncholinergic effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 210000000192 parasympathetic ganglia Anatomy 0.000 description 2
- 239000013618 particulate matter Substances 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000003518 presynaptic effect Effects 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000004739 secretory vesicle Anatomy 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 210000005070 sphincter Anatomy 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000000225 synapse Anatomy 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001839 systemic circulation Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 102100038518 Calcitonin Human genes 0.000 description 1
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241001112695 Clostridiales Species 0.000 description 1
- 241001509415 Clostridium botulinum A Species 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000736355 Euthyroides Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108091052347 Glucose transporter family Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010018687 Granulocytopenia Diseases 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 101000963974 Hydrophis stokesii Alpha-elapitoxin-Ast2b Proteins 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000004404 Intractable Pain Diseases 0.000 description 1
- 206010067997 Iodine deficiency Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 208000024297 Laryngeal Nerve injury Diseases 0.000 description 1
- 206010025282 Lymphoedema Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010027603 Migraine headaches Diseases 0.000 description 1
- 208000034819 Mobility Limitation Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 101000964025 Naja naja Long neurotoxin 3 Proteins 0.000 description 1
- 101000822778 Naja naja Long neurotoxin 4 Proteins 0.000 description 1
- 101000822797 Naja naja Long neurotoxin 5 Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 208000014993 Pituitary disease Diseases 0.000 description 1
- 208000021738 Plummer disease Diseases 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 101000930762 Sulfolobus acidocaldarius (strain ATCC 33909 / DSM 639 / JCM 8929 / NBRC 15157 / NCIMB 11770) Signal recognition particle receptor FtsY Proteins 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 108010055044 Tetanus Toxin Proteins 0.000 description 1
- 208000003217 Tetany Diseases 0.000 description 1
- 206010043784 Thyroiditis subacute Diseases 0.000 description 1
- 206010044242 Toxic nodular goitre Diseases 0.000 description 1
- 206010056397 Tracheomalacia Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 101710102828 Vesicle-associated protein Proteins 0.000 description 1
- 101710097943 Viral-enhancing factor Proteins 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 208000005248 Vocal Cord Paralysis Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010051373 Wound haemorrhage Diseases 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000003916 acid precipitation Methods 0.000 description 1
- -1 acids and magnesium Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 210000004079 adrenergic fiber Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000003502 anti-nociceptive effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 208000010928 autoimmune thyroid disease Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 230000035563 calcemia Effects 0.000 description 1
- 210000001540 calcitonin secreting cell Anatomy 0.000 description 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
- 230000003913 calcium metabolism Effects 0.000 description 1
- 208000022458 calcium metabolism disease Diseases 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- CFOYWRHIYXMDOT-UHFFFAOYSA-N carbimazole Chemical compound CCOC(=O)N1C=CN(C)C1=S CFOYWRHIYXMDOT-UHFFFAOYSA-N 0.000 description 1
- 229960001704 carbimazole Drugs 0.000 description 1
- 210000000269 carotid artery external Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000004889 cervical nerve Anatomy 0.000 description 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000003737 chromaffin cell Anatomy 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 231100001102 clostridial toxin Toxicity 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 210000005080 cortical synaptosome Anatomy 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 208000029444 double vision Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 210000002409 epiglottis Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 208000001936 exophthalmos Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 230000000574 ganglionic effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000001184 hypocalcaemic effect Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 235000006479 iodine deficiency Nutrition 0.000 description 1
- 229940036571 iodine therapy Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004717 laryngeal muscle Anatomy 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 230000008095 long lasting therapeutic effect Effects 0.000 description 1
- 208000002502 lymphedema Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 210000000337 motor cortex Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000008035 nerve activity Effects 0.000 description 1
- 230000007383 nerve stimulation Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000018360 neuromuscular disease Diseases 0.000 description 1
- 210000001719 neurosecretory cell Anatomy 0.000 description 1
- 230000000720 neurosecretory effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 206010030875 ophthalmoplegia Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 210000005034 parasympathetic neuron Anatomy 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 208000017402 pituitary gland disease Diseases 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229940045662 porcine thyroid Drugs 0.000 description 1
- 210000001089 postganglionic sympathetic fiber Anatomy 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 208000007884 postpartum thyroiditis Diseases 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 231100000654 protein toxin Toxicity 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 210000002763 pyramidal cell Anatomy 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000003019 respiratory muscle Anatomy 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000018528 secretion by tissue Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 108010010958 snake venom neurotoxin F Proteins 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000003270 subclavian artery Anatomy 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 230000002782 sympathoadrenal effect Effects 0.000 description 1
- 210000003568 synaptosome Anatomy 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 229940099247 tapazole Drugs 0.000 description 1
- 210000000966 temporal muscle Anatomy 0.000 description 1
- 238000009601 thyroid function test Methods 0.000 description 1
- 229940032953 thyroid therapy drug Drugs 0.000 description 1
- 208000013076 thyroid tumor Diseases 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 229950001470 thyrotrophin Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- ATCJTYORYKLVIA-SRXJVYAUSA-N vamp regimen Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C(C45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 ATCJTYORYKLVIA-SRXJVYAUSA-N 0.000 description 1
- 210000005203 vein jugularis anteriores Anatomy 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/504,538 | 2000-02-15 | ||
| US09/504,538 US6524580B1 (en) | 2000-02-15 | 2000-02-15 | Method for treating thyroid disorders |
| PCT/US2001/004990 WO2001060396A2 (en) | 2000-02-15 | 2001-02-15 | Method for treating thyroid disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012145866A Division JP2012207030A (ja) | 2000-02-15 | 2012-06-28 | 甲状腺疾患の治療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003530320A true JP2003530320A (ja) | 2003-10-14 |
| JP2003530320A5 JP2003530320A5 (https=) | 2008-04-10 |
Family
ID=24006701
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001559492A Pending JP2003530320A (ja) | 2000-02-15 | 2001-02-15 | 甲状腺疾患の治療法 |
| JP2012145866A Pending JP2012207030A (ja) | 2000-02-15 | 2012-06-28 | 甲状腺疾患の治療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012145866A Pending JP2012207030A (ja) | 2000-02-15 | 2012-06-28 | 甲状腺疾患の治療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (6) | US6524580B1 (https=) |
| EP (1) | EP1253933B1 (https=) |
| JP (2) | JP2003530320A (https=) |
| AR (1) | AR027442A1 (https=) |
| AT (1) | ATE245032T1 (https=) |
| AU (1) | AU2001238369A1 (https=) |
| DE (1) | DE60100473T2 (https=) |
| ES (1) | ES2199209T3 (https=) |
| TW (1) | TWI283177B (https=) |
| WO (1) | WO2001060396A2 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013060450A (ja) * | 2005-06-17 | 2013-04-04 | Allergan Inc | 神経毒による自己免疫疾患の治療 |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1251867A4 (en) | 2000-02-04 | 2004-12-08 | Unigene Lab Inc | NASAL CALCITON INFORMATION |
| US6821520B2 (en) * | 2000-02-15 | 2004-11-23 | Allergan, Inc. | Clostridial toxin therapy for Hashimoto's thyroiditis |
| US6524580B1 (en) * | 2000-02-15 | 2003-02-25 | Allergan Sales, Inc. | Method for treating thyroid disorders |
| US6773711B2 (en) * | 2000-02-15 | 2004-08-10 | Allergan, Inc. | Botulinum toxin therapy for Hashimoto's thyroiditis |
| US8563257B2 (en) * | 2000-03-30 | 2013-10-22 | Diagnostic Hybrids, Inc. | Sensitive and rapid methods of using chimeric receptors to identify autoimmune disease and assess disease severity |
| US8293879B2 (en) | 2000-03-30 | 2012-10-23 | Diagnostic Hybrids, Inc. | Methods of using chimeric receptors to identify autoimmune disease |
| WO2002000172A2 (en) * | 2000-06-28 | 2002-01-03 | Ira Sanders | Methods for using tetanus toxin for benificial purposes in animals (mammals) |
| US6921538B2 (en) * | 2002-05-10 | 2005-07-26 | Allergan, Inc. | Therapeutic treatments for neuropsychiatric disorders |
| US7178059B2 (en) * | 2003-05-07 | 2007-02-13 | Egenera, Inc. | Disaster recovery for processing resources using configurable deployment platform |
| US20040226556A1 (en) * | 2003-05-13 | 2004-11-18 | Deem Mark E. | Apparatus for treating asthma using neurotoxin |
| US7220422B2 (en) * | 2003-05-20 | 2007-05-22 | Allergan, Inc. | Methods and compositions for treating eye disorders |
| US8137924B2 (en) * | 2003-12-19 | 2012-03-20 | Wisconsin Alumni Research Foundation | Method and compositions for detecting botulinum neurotoxin |
| US7514088B2 (en) * | 2005-03-15 | 2009-04-07 | Allergan, Inc. | Multivalent Clostridial toxin derivatives and methods of their use |
| US7811584B2 (en) * | 2004-06-30 | 2010-10-12 | Allergan, Inc. | Multivalent clostridial toxins |
| EP1982997B1 (en) | 2004-09-01 | 2012-08-08 | Allergan, Inc. | Degradable clostridial toxins |
| EP1871789B1 (en) | 2005-03-15 | 2013-11-06 | Allergan, Inc. | Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells |
| JP5826450B2 (ja) | 2005-07-22 | 2015-12-02 | ザ ファウンドリー， エルエルシー | 治療薬の送達のためのシステムおよび方法 |
| US7655243B2 (en) | 2005-07-22 | 2010-02-02 | The Foundry, Llc | Methods and systems for toxin delivery to the nasal cavity |
| US10052465B2 (en) | 2005-07-22 | 2018-08-21 | The Foundry, Llc | Methods and systems for toxin delivery to the nasal cavity |
| US12433837B2 (en) | 2005-07-22 | 2025-10-07 | The Foundry, Llc | Systems and methods for delivery of a therapeutic agent |
| US7708699B2 (en) * | 2005-11-18 | 2010-05-04 | Daag International, Inc. | Reflexometry and hormone function |
| US8483831B1 (en) | 2008-02-15 | 2013-07-09 | Holaira, Inc. | System and method for bronchial dilation |
| US8470337B2 (en) * | 2008-03-13 | 2013-06-25 | Allergan, Inc. | Therapeutic treatments using botulinum neurotoxin |
| US8088127B2 (en) | 2008-05-09 | 2012-01-03 | Innovative Pulmonary Solutions, Inc. | Systems, assemblies, and methods for treating a bronchial tree |
| RU2446791C2 (ru) * | 2009-06-18 | 2012-04-10 | Федеральное государственное учреждение "Северо-Западный окружной медицинский центр Минздравсоцразвития" | Способ этаноловой склеротерапии кистозно-трансформированных узлов щитовидной железы |
| AU2010315396B2 (en) | 2009-10-27 | 2016-05-05 | Nuvaira, Inc | Delivery devices with coolable energy emitting assemblies |
| JP6000851B2 (ja) | 2009-11-11 | 2016-10-05 | ホライラ， インコーポレイテッド | 組織治療および狭窄制御のためのシステム、装置、および方法 |
| US8911439B2 (en) | 2009-11-11 | 2014-12-16 | Holaira, Inc. | Non-invasive and minimally invasive denervation methods and systems for performing the same |
| US9011323B2 (en) * | 2010-10-08 | 2015-04-21 | Invuity, Inc. | Method and apparatus for soft tissue retraction |
| EP2836193B1 (en) | 2012-04-13 | 2018-01-31 | Lubrizol Advanced Materials, Inc. | Compounds which inhibit neuronal exocytosis (ii) |
| EP2649985A1 (en) | 2012-04-13 | 2013-10-16 | Lipotec, S.A. | Compounds which inhibit neuronal exocytosis (III) |
| EP2649984A1 (en) | 2012-04-13 | 2013-10-16 | Lipotec, S.A. | Compounds which inhibit neuronal exocytosis |
| EP2649983A1 (en) | 2012-04-13 | 2013-10-16 | Lipotec, S.A. | Compounds which inhibit neuronal exocytosis (II) |
| US9005628B2 (en) | 2012-10-04 | 2015-04-14 | Dublin City University | Biotherapy for pain |
| US9398933B2 (en) | 2012-12-27 | 2016-07-26 | Holaira, Inc. | Methods for improving drug efficacy including a combination of drug administration and nerve modulation |
| GB201312317D0 (en) | 2013-07-09 | 2013-08-21 | Syntaxin Ltd | Cationic neurotoxins |
| US9216210B2 (en) | 2013-12-23 | 2015-12-22 | Dublin City University | Multiprotease therapeutics for chronic pain |
| CN107108703B (zh) | 2015-01-09 | 2022-09-23 | 益普生生物创新有限公司 | 阳离子神经毒素 |
| US9855317B2 (en) | 2015-04-27 | 2018-01-02 | Reflex Medical, Inc. | Systems and methods for sympathetic cardiopulmonary neuromodulation |
| GB201517450D0 (en) | 2015-10-02 | 2015-11-18 | Ipsen Biopharm Ltd | Method |
| GB201607901D0 (en) | 2016-05-05 | 2016-06-22 | Ipsen Biopharm Ltd | Chimeric neurotoxins |
| EP3263710A1 (en) | 2016-07-01 | 2018-01-03 | Ipsen Biopharm Limited | Production of activated clostridial neurotoxins |
| WO2018060351A1 (en) | 2016-09-29 | 2018-04-05 | Ipsen Biopharm Limited | Hybrid neurotoxins |
| WO2019162696A1 (en) | 2018-02-26 | 2019-08-29 | Ipsen Biopharm Limited | Use of ultrasound to guide injection of non-cytotoxic protease |
| DE102019215585B4 (de) * | 2019-10-10 | 2022-02-17 | KCM Egészségügyi és Tudományos Korlátolt Felelösségü Társaság | Verfahren zur prävention von strahlenschäden in humanen drüsen |
| GB202103372D0 (en) | 2021-03-11 | 2021-04-28 | Ipsen Biopharm Ltd | Modified clostridial neurotoxins |
| AU2022252296A1 (en) | 2021-03-30 | 2023-09-21 | Tulavi Therapeutics, Inc. | Methods and compositions for the ablation of nerves |
| GB202318884D0 (en) | 2023-12-11 | 2024-01-24 | Ipsen Biopharm Ltd | Formulation |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6022544A (en) | 1983-01-24 | 2000-02-08 | The John Hopkins University | Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry |
| US5786348A (en) * | 1991-01-08 | 1998-07-28 | Bone Care International, Inc. | Methods for preparation and use of 1α,24(S)-dihydroxy vitamin D2 |
| ES2107051T3 (es) | 1992-09-21 | 1997-11-16 | Upjohn Co | Formulaciones de proteinas de liberacion sostenida. |
| WO1994012158A1 (en) | 1992-12-02 | 1994-06-09 | Alkermes Controlled Therapeutics, Inc. | Controlled release growth hormone containing microspheres |
| EP1099445A3 (en) * | 1993-06-10 | 2001-09-05 | Allergan, Inc. | Treatment of neuromuscular disorders and conditions with different botulinum serotype |
| US5437291A (en) | 1993-08-26 | 1995-08-01 | Univ Johns Hopkins | Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction |
| ES2332905T3 (es) * | 1993-12-28 | 2010-02-15 | Allergan, Inc. | Uso del componente neurotoxico de la toxina botulinica para el tratamiento de trastornos de musculos lisos. |
| US5766605A (en) | 1994-04-15 | 1998-06-16 | Mount Sinai School Of Medicine Of The City University Of New York | Treatment of autonomic nerve dysfunction with botulinum toxin |
| US6007843A (en) | 1995-09-29 | 1999-12-28 | Lam Pharmaceuticals Corp. | Sustained release delivery system |
| US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
| EP1011695B2 (en) | 1997-07-15 | 2009-11-04 | The Regents of the University of Colorado | Use of neurotoxin therapy for treatment of prostate disorders |
| US6063768A (en) | 1997-09-04 | 2000-05-16 | First; Eric R. | Application of botulinum toxin to the management of neurogenic inflammatory disorders |
| US6022554A (en) | 1997-12-15 | 2000-02-08 | American Home Products Corporation | Polymeric microporous film coated subcutaneous implant |
| GB9818548D0 (en) | 1998-08-25 | 1998-10-21 | Microbiological Res Authority | Treatment of mucas hypersecretion |
| US6432723B1 (en) * | 1999-01-22 | 2002-08-13 | Clinical Micro Sensors, Inc. | Biosensors utilizing ligand induced conformation changes |
| US6358513B1 (en) * | 2000-02-15 | 2002-03-19 | Allergan Sales, Inc. | Method for treating Hashimoto's thyroiditis |
| US6524580B1 (en) * | 2000-02-15 | 2003-02-25 | Allergan Sales, Inc. | Method for treating thyroid disorders |
| US6649161B1 (en) * | 2000-02-22 | 2003-11-18 | Allergan, Inc. | Method for treating hypocalcemia |
| US6432623B1 (en) * | 2001-04-27 | 2002-08-13 | Eastman Kodak Company | Method for processing a photographic element comprising a simultaneously coated protective overcoat |
-
2000
- 2000-02-15 US US09/504,538 patent/US6524580B1/en not_active Expired - Fee Related
- 2000-11-02 US US09/706,172 patent/US6743424B1/en not_active Expired - Fee Related
- 2000-11-02 US US09/706,174 patent/US6447785B1/en not_active Expired - Fee Related
- 2000-11-02 US US09/706,211 patent/US6740321B1/en not_active Expired - Fee Related
- 2000-11-02 US US09/706,173 patent/US6585970B1/en not_active Expired - Fee Related
- 2000-11-02 US US09/706,215 patent/US6716427B1/en not_active Expired - Fee Related
-
2001
- 2001-02-14 TW TW090103247A patent/TWI283177B/zh not_active IP Right Cessation
- 2001-02-15 AT AT01910800T patent/ATE245032T1/de not_active IP Right Cessation
- 2001-02-15 AU AU2001238369A patent/AU2001238369A1/en not_active Abandoned
- 2001-02-15 AR ARP010100698A patent/AR027442A1/es unknown
- 2001-02-15 JP JP2001559492A patent/JP2003530320A/ja active Pending
- 2001-02-15 DE DE60100473T patent/DE60100473T2/de not_active Expired - Lifetime
- 2001-02-15 ES ES01910800T patent/ES2199209T3/es not_active Expired - Lifetime
- 2001-02-15 EP EP01910800A patent/EP1253933B1/en not_active Expired - Lifetime
- 2001-02-15 WO PCT/US2001/004990 patent/WO2001060396A2/en not_active Ceased
-
2012
- 2012-06-28 JP JP2012145866A patent/JP2012207030A/ja active Pending
Non-Patent Citations (1)
| Title |
|---|
| JPN6010066728, Ｂｒ． Ｊ． Ｏｐｈｔｈａｌｍｏｌ．, 1998, Ｖｏｌ．８２, ｐｐ．５２８−３３ * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013060450A (ja) * | 2005-06-17 | 2013-04-04 | Allergan Inc | 神経毒による自己免疫疾患の治療 |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2199209T3 (es) | 2004-02-16 |
| TWI283177B (en) | 2007-07-01 |
| AR027442A1 (es) | 2003-03-26 |
| US6743424B1 (en) | 2004-06-01 |
| US6524580B1 (en) | 2003-02-25 |
| JP2012207030A (ja) | 2012-10-25 |
| WO2001060396A2 (en) | 2001-08-23 |
| WO2001060396A3 (en) | 2002-03-14 |
| AU2001238369A1 (en) | 2001-08-27 |
| US6447785B1 (en) | 2002-09-10 |
| US6716427B1 (en) | 2004-04-06 |
| US6740321B1 (en) | 2004-05-25 |
| ATE245032T1 (de) | 2003-08-15 |
| US6585970B1 (en) | 2003-07-01 |
| DE60100473T2 (de) | 2004-04-15 |
| DE60100473D1 (de) | 2003-08-21 |
| EP1253933A2 (en) | 2002-11-06 |
| EP1253933B1 (en) | 2003-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6716427B1 (en) | Method for treating hypocalcemia | |
| US6368605B1 (en) | Method for treating cancer with a neurotoxin to improve patient function | |
| US6358513B1 (en) | Method for treating Hashimoto's thyroiditis | |
| US6319506B1 (en) | Method for treating hypercalcemia | |
| ES2287117T3 (es) | Uso de una toxina botulinica pra la fabricacion de un medicamento de administracion periferica para tratar dolor no asociado al espasmo muscular ni al dolor de cabeza. | |
| JP4851042B2 (ja) | 糖尿病の治療方法 | |
| MX2007002127A (es) | Metodos para el tratamiento de cancer. | |
| JP4602762B2 (ja) | 持続勃起症を処置するためのボツリヌス毒素 | |
| JP2012116839A (ja) | 膵臓障害の処置方法 | |
| US6773711B2 (en) | Botulinum toxin therapy for Hashimoto's thyroiditis | |
| KR101211890B1 (ko) | 보툴리눔 독소를 사용한 튼살의 처치방법 | |
| WO2002009743A1 (en) | Method for treating a neoplasm | |
| US6821520B2 (en) | Clostridial toxin therapy for Hashimoto's thyroiditis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080213 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080213 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101130 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110228 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110307 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110331 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110407 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110428 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110511 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110531 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110621 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110921 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110929 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111020 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111027 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111118 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111128 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120228 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120628 |